NEW YORK, Feb. 5 - Protein Design Labs will acquire Eos Biotechnology in an all-stock transaction valued at $37.5 million, the Fremont, Calif., company said yesterday.
The merger is expected to close in the first quarter of 2003, subject to regulatory approval.
Protein Design Labs develops therapeutic antibodies for cancer treatment and immunologic disorders. Eos Biotechnology, of South San Francisco, uses its proprietary genomics platform to identify novel disease targets and develop antibodies.
Click here for more information.